Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on SAM. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103014081A details a green enzymatic route for 3-amino-4-(2,4,5-trifluorophenyl)methyl butyrate, offering superior chirality and cost reduction in pharmaceutical intermediate manufacturing.
Novel synthesis route for 2-deoxy-D-glucose via glucosamine. Reduces cost and complexity. Ideal for API manufacturing scale-up and high-purity production.
Patent CN110951706B details a high-activity R-omega-TA mutant for sitagliptin. Offers high ee value >99%, breaking technical monopolies and ensuring supply chain stability.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN117701523A reveals solvent-tolerant transaminase for high-purity sitagliptin intermediate manufacturing with significant supply chain cost reduction.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Patent CN115304506A reveals a green boron-catalyzed transamidation method. Achieve high-purity secondary amides with reduced costs and simplified supply chains for pharmaceutical manufacturing.
Novel enzymatic route for (S,S)-2,8-diazabicyclo[4,3,0]nonane. Reduces steps, avoids high-pressure hydrogenation. Reliable pharma intermediate supplier.
Patent CN117660389A reveals mutant transaminase for chiral amines. Offers high conversion and purity for pharma and agrochemical manufacturing supply chains.
Novel radical-initiated method reduces isomers and simplifies deprotection for scalable API intermediate manufacturing ensuring high purity and supply chain reliability for global pharmaceutical partners.
Novel patent CN118955585A offers scalable D-mannosamine production. Reduces purification steps, enhances supply chain reliability for pharmaceutical intermediates.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN115896060A reveals a novel ω-transaminase mutant for silodosin synthesis, offering >99% ee and scalable biocatalysis for reliable supply chains.
Patent CN113045393B details a novel Diels-Alder cascade for aromatic polyketones. Enables cost-effective API intermediate manufacturing with scalable chemistry.
Novel synthesis method for glucosamine derivatives avoids hazardous reagents and column chromatography ensuring high purity and scalable industrial production for reliable supply.
Patent CN1898193A details a lithium-catalyzed method for producing bisamido alcohols, offering a safer, high-yield alternative to acyl chloride routes for asymmetric catalyst ligands.